Rx Medicare

HHS Secretary Kathleen Sebelius announced today that the department will take important steps necessary to prepare for potential commercial-scale production of a candidate vaccine for the novel Influenza A ( H1N1). The Secretary is directing approximately $1 billion in existing funds that will be used for clinical studies that will take place over the summer and for commercial-scale production of two potential vaccine ingredients for the pre-pandemic influenza stockpile.

Read More…

Related Posts

• FDA Approves Additional Vaccine For 2009 H1N1 Influenza Virus
• As Influenza Cases Rise In Europe, Experts Urge Uptake Of H1N1 Vaccine
• CSL Biotherapies Obtains FDA Licensure For Use Of Its Thimerosal-Free Pandemic Influenza A (H1N1) 2009 Monovalent Vaccine In Children
• Get Smart About Swine Flu H1N1 Swine Flu Vaccine Influenza P
• MANUFACTURING THE H1N1 FLU VACCINE NASAL SPRAY Influenza
• Practice Fusion Identifies 300,000 High-Risk Patients For H1N1 Influenza Vaccine, In-line With CDC Pandemic Guidelines
• Baxter Receives European Commission Approval For CELVAPAN H1N1 Pandemic Influenza Vaccine
• Three Additional Alabama Deaths Linked To 2009 H1N1 Influenza
• Baxter Receives EMEA Positive Opinion For CELVAPAN H1N1 Pandemic Influenza Vaccine
• Additional Alabama Death Linked To 2009 H1N1 Influenza
• Novel H1N1 Influenza Is Widespread In Alabama; Health Care System Is Handling It Well
• Additional Alabama Deaths Linked To 2009 H1N1 Influenza
• Second Alabama Child Dies From Novel H1N1 Influenza
• Novel H1N1 Influenza A (Swine Flu) Update For Arkansans
• Swine Flu: NIAID Set To Launch Clinical Trials To Test 2009 H1N1 Influenza Vaccine Candidates

Tags: additional, development, efficacy, h1n1, influenza, novel, steps, takes, toward, vaccine

This entry was posted on Tuesday, May 26th, 2009 at 3:05 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.